HIV Fusion Inhibitors

Inhibitors of the fusion of HIV to host cells, preventing viral entry. This includes compounds that block attachment of HIV ENVELOPE PROTEIN GP120 to CD4 RECEPTORS.

Also Known As:

HIV Cell Fusion Inhibitors; HIV Fusion Protein Inhibitors; Entry Inhibitor, HIV; Entry Inhibitors, HIV; Fusion Inhibitor, HIV; Inhibitor, HIV Entry; Inhibitor, HIV Fusion; Fusion Inhibitors, HIV; HIV Cell Fusion Inhibitor; HIV Entry Inhibitor; HIV Entry Inhibitors; HIV Fusion Inhibitor; HIV Fusion Protein Inhibitor

Networked: 40 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Therapeutic Uses: 47080
    - Anti-Infective Agents: 8032
      - Antiviral Agents: 47706
        Anti-Retroviral Agents: 656
        Anti-HIV Agents: 514
        HIV Fusion Inhibitors: 40
        Viral Fusion Protein Inhibitors
        HIV Fusion Inhibitors: 40
  - Molecular Mechanisms of Pharmacological Action: 24
    - Viral Fusion Protein Inhibitors
      - HIV Fusion Inhibitors: 40

Experts

1.	Jiang, Shibo: 9 articles (01/2022 - 01/2002)
2.	Wang, Qian: 3 articles (01/2022 - 08/2015)
3.	Fujii, Nobutaka: 3 articles (01/2007 - 07/2004)
4.	Tamamura, Hirokazu: 3 articles (01/2007 - 07/2004)
5.	Pu, Jing: 2 articles (01/2022 - 01/2019)
6.	Lu, Lu: 2 articles (01/2019 - 08/2015)
7.	Xu, Wei: 2 articles (01/2019 - 08/2015)
8.	Du, Lanying: 2 articles (08/2015 - 08/2013)
9.	Yu, Fei: 2 articles (08/2015 - 08/2013)
10.	Balzarini, Jan: 2 articles (09/2012 - 05/2005)

Related Diseases

1.	Infections 03/01/2016 - "A screen of a 1998 known-biological profile small molecule library identified pharmacological HIV entry inhibitors that block both cell-free and cell-to-cell infection. " 08/01/2009 - "Therefore, these findings strongly imply that, rather than replacing T20, combining it with HIV fusion inhibitors of different generations might produce synergistic activity against both T20-sensitive and -resistant HIV-1 strains, suggesting a new therapeutic strategy for the treatment of HIV-1 infection/AIDS." 10/21/2008 - "On the basis of the structural and functional information of anti-HIV peptides from a previous study, we designed an HIV fusion inhibitor named CP32M, a 32-mer synthetic peptide that is highly effective in inhibiting infection by a wide range of primary HIV-1 isolates from multiple genotypes with R5- or dual-tropic (R5X4) phenotype, including a group O virus (BCF02) that is resistant to T20 and C34 (another anti-HIV peptide). " 09/22/2020 - "Correction for Nishimura et al., Prevention and treatment of SHIVAD8 infection in rhesus macaques by a potent d-peptide HIV entry inhibitor." 01/01/2020 - "Prevention and treatment of SHIVAD8 infection in rhesus macaques by a potent d-peptide HIV entry inhibitor."
2.	Acquired Immunodeficiency Syndrome (AIDS) 01/01/2019 - "The HIV fusion inhibitor T20 has been approved to treat those living with HIV/AIDS, but treatment gives rise to resistant viruses. " 01/01/2001 - "HIV fusion inhibitors for AIDS therapy." 08/01/2009 - "Therefore, these findings strongly imply that, rather than replacing T20, combining it with HIV fusion inhibitors of different generations might produce synergistic activity against both T20-sensitive and -resistant HIV-1 strains, suggesting a new therapeutic strategy for the treatment of HIV-1 infection/AIDS." 09/01/2003 - "This review summarizes the current state of HIV entry inhibitors, their mechanisms of action and their therapeutic value against HIV infection and AIDS." 08/19/2015 - "Enfuvirtide (T20), is the first HIV fusion inhibitor approved for treatment of HIV/AIDS patients who fail to respond to the current antiretroviral drugs. "
3.	HIV Infections (HIV Infection) 02/01/2012 - "In this review, we describe the HIV entry process and provide an overview of the different classes of approved HIV entry inhibitors while highlighting novel genetic strategies aimed at blocking HIV infection at the level of entry." 10/15/2007 - "This article details the development of the HIV entry inhibitors, describing the physiology and pharmacology involved in their design, and their use in individuals at all stages of HIV infection. " 01/01/2002 - "[Coreceptors of HIV infection and the development of HIV entry inhibitors: overview and targets]." 09/01/2003 - "This review summarizes the current state of HIV entry inhibitors, their mechanisms of action and their therapeutic value against HIV infection and AIDS." 06/01/2007 - "BMS-378806 is a human immunodeficiency virus (HIV) entry inhibitor that is being developed for the oral treatment of HIV infection. "
4.	Neoplasms (Cancer) 11/01/2015 - "Dennis Liotta, who received the Holý award, described how an investigation into HIV entry inhibitors led to a new therapy for cancer patients. " 07/02/2004 - "Analogs of the 14-mer peptide T140 were previously found to be specific CXCR4 antagonists that were characterized as not only HIV-entry inhibitors but also anti-cancer-metastatic agents. " 12/15/2020 - "CADA compounds selectively down-modulate human cell-surface CD4 protein and are of interest as HIV entry inhibitors and as drugs for asthma, rheumatoid arthritis, diabetes and some cancers. " 01/01/2011 - "Compounds that block CXCR4 interactions have potential uses as HIV entry inhibitors to complement drugs such as maraviroc that block the alternate coreceptor CCR5 or in cancer therapy. " 01/01/2007 - "Fourteen-mer peptides, T140 and its analogs, were previously found to be specific CXCR4 antagonists that were characterized as HIV-entry inhibitors, anti-cancer-metastatic agents, anti-chronic lymphocytic/acute lymphoblastic leukemia agents and anti-RA agents. "
5.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/01/2007 - "Fourteen-mer peptides, T140 and its analogs, were previously found to be specific CXCR4 antagonists that were characterized as HIV-entry inhibitors, anti-cancer-metastatic agents, anti-chronic lymphocytic/acute lymphoblastic leukemia agents and anti-RA agents. " 01/01/2007 - "Fourteen-mer peptides, T140 and its analogues, were previously developed in our laboratory as specific CXCR4 antagonists that were identified as HIV-entry inhibitors, anti-cancer-metastatic agents, anti-chronic lymphocytic/acute lymphoblastic leukemia agents, and anti-RA agents. "

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	Proteins (Proteins, Gene)
3.	Vaginal Creams, Foams, and Jellies (Vaginal Tablet)
4.	cellulose sulfate
5.	Enfuvirtide (Fuzeon)
6.	Antiviral Agents (Antivirals)
7.	T140 peptide
8.	HIV Reverse Transcriptase
9.	Reverse Transcriptase Inhibitors
10.	Protease Inhibitors (Protease Inhibitor)

Related Therapies and Procedures

1.	Therapeutics
2.	Salvage Therapy
3.	Injections